<DOC>
	<DOCNO>NCT00551798</DOCNO>
	<brief_summary>Predicting response chemotherapy patient Hodgkin 's disease lymphoma high-grade malignant de novo recurrence . The non-Hodgkin 's lymphoma high-grade Hodgkin 's disease may show resistance chemotherapy , regardless initial extension . The failure treatment often correlate incomplete answer lack response chemotherapy result chemoresistance . This drug , may involve gene MDR1 ( multidrug resistance ) encode protein PGP , study vivo MIBI scan . The MIBI behind tracer perfusionnel use routinely explore myocardial perfusion , characteristic fixing , use oncological imaging ( fixation glial tumor high grade ) .Prospective Study , include conduct tomoscintigraphie 30 minute injection 20 mCi 99mTc-MIBI initial stock relapse high-grade lymphoma Hodgkin 's disease stage ( I-IV ) . Fixing MIBI compare morphological abnormality detect CT set lesion 18FDG . Patients treat traditional way , without change treatment protocol use routine . Patients negative MIBI scan , watch particular attention order detect insufficient response chemotherapy . The change , care patient , achievement initial consideration non-invasive imaging , , tomoscintigraphie MIBI . Of tumor sample , evaluate immunohistochemistry , expression PGP MRP1 ( two protein associate drug ) . On blood , may carry genotyping MDR1 , MRP1 MRP2 patient .</brief_summary>
	<brief_title>Prediction Response Chemotherapy Tomoscintigraphie MIBI Balance Sheet Pre Hodgkin 's Disease Lymphoma Malins High Grade</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>initial Attainment : Highgrade NHL Hodgkin 's disease stage : I , II , III et IV . Relapse : Highgrade NHL Hodgkin 's disease relapse stage : I , II , III et IV . Patients recruit Network clinical hematology du Limousin Patients old 18 year without brain damage Pregnant woman nurse mother without effective contraception Patients without coverage social security Patients start steroid refer antitumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>Hodgkin 's Disease</keyword>
	<keyword>Malignant lymphomas high grade</keyword>
	<keyword>Chemoresistance</keyword>
	<keyword>MIBI</keyword>
	<keyword>PGP</keyword>
	<keyword>MRP1</keyword>
	<keyword>Tumor response</keyword>
</DOC>